FPG and HbA1c values did not, however, increase over 86 weeks, and there were no new cases of diabetes in the subjects treated with somapacitan, in line with results from an earlier 26-week trial of once-weekly somapacitan versus daily GH (18). The gene discussed is GH1; the disease is diabetes mellitus.